Table 3.
Patient clinical characteristics and methods used in studies reporting MTV in DLBCL
| N | PFS and OS of study cohort (%) | % > 60 y | % Stage III/IV | % Bulk | IPI | PS ≥ 2 | Treatment | Method | Cut-off (cm3) | PFS by MTV (%) | OS by MTV (%) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Song 2011 [25] | 169 | At 3 y: PFS 74 OS 76 |
60 | 41% stage III, no stage IV or I |
4% ≥ 5 cm |
26% ≥ 3 |
25% | RCHOP | SUV ≥ 2.5 | 220 | At 3 y: 90 vs. 56** |
At 3 y: 93 vs. 58** |
| Sasanelli 2014 [24] | 114 | NA | 31 | 82 | 36% ≥ 10 cm |
65% ≥ 2 (aaIPI) |
30% | RCHOP/RACVBP | ≥ 41% SUVmax |
550 | At 3 y: 77 vs. 60 |
At 3 y: 87 vs. 60** |
| Song 2016 [38] | 107 | NA | 67 | 100% had BMI | 19% | 81 ≥ 4 (NCCN-IPI) |
16% | RCHOP | SUV ≥ 2.5 | 600 | At 2 y: ~ 80 vs. 20%** | At 2 y: ~ 80 vs. 20%** |
| Cottereau 2016 [24] | 81 | At 5 y: PFS 60 OS 63 |
63 | 80 | 40% ≥ 10 cm |
68% ≥ 2 (aaIPI) |
30% | RCHOP/RACVBP | ≥ 41% SUVmax |
300 | At 5 y: 75 vs. 42 |
At 5 y: 78 vs. 46** |
| Mikhaeel [26] and current study | 147 | At 5 y: PFS 65 OS 74 |
48 | 69 | 40% ≥ 10 cm |
69% ≥ 2 | 30% | RCHOP | SUV ≥ 2.5 | 400 | At 5 y: 87 vs. 42 ** |
At 5 y: 89 vs. 55 ** |
**Independent predictor in multivariate analysis for survival
BMI – bone marrow involvement, PS - performance status, RCHOP - rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone, RACVBP – rituximab and doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone